> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Schedules Public Hearing on Commissioner’s Voucher Program
- URL: https://www.fdaweb.com/fda-schedules-public-hearing-on-commissioners-voucher-program/
- Published: 2026-03-20T12:00:00.000Z
- Updated: 2026-09-14T13:35:54.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160855

FDA is announcing a 6/12 [public hearing](https://www.fda.gov/news-events/commissioners-national-priority-voucher-cnpv-pilot-program-public-hearing-06122026?utm%5Fmedium=email&utm%5Fsource=govdelivery) to gather input on its Commissioner’s National Priority Voucher (CNPV) Pilot Program, aimed at streamlining review of therapies for critical public health needs. The pilot is designed to explore faster review pathways for certain high-priority medical products. During the hearing, stakeholders will be invited to provide feedback on program eligibility criteria, voucher selection processes, sponsor responsibilities, FDA review procedures, and overall implementation.

The program has been faced with questions about its long-term impact, with some policy experts warning the program could expose the agency’s approval process to legal challenges and regulatory uncertainty. The initiative, launched last June by FDA commissioner **Marty Makary**, offers selected drug developers an “ultra-fast” review timeline of one to two months — far shorter than the typical six- to ten-month review window for most new drug applications.

Under the CNPV program, FDA leadership selects specific drug candidates for accelerated review and critics say the selection process lacks transparency and could create the perception of political influence over scientific review decisions, according to article by former FDA official Grail Sipes [posted](https://petrieflom.law.harvard.edu/2026/03/13/hazards-ahead-for-fdas-drug-review-process/?ref=fdaweb.com) by Harvard Law School’s The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics.

According to internal guidance issued after the program’s launch, an official in the commissioner’s office documents the rationale for each voucher selection, but those records are not publicly released, Grail says. In some cases, the agency has reportedly awarded vouchers proactively rather than in response to company applications. Public health experts and some industry observers argue that the criteria guiding the program’s selections remain loosely defined and may extend beyond the FDA’s traditional regulatory mission. They also question whether a one- to two-month review period allows sufficient time to fully evaluate a drug’s safety and effectiveness.

Sipes says the program may face challenges in federal court, particularly because it lacks explicit statutory authorization. Congress is expected to revisit FDA funding and performance goals during the drug user fee reauthorization, which must be enacted by 9/30/2027, adding that lawmakers could choose to codify, modify, or eliminate the voucher system as part of that process.

In the meantime, companies that are not selected for vouchers could argue that the FDA is treating similar drug applications differently or diverting agency resources to competing products as a legal strategy. Sipes says another potential avenue for litigation stems from the U.S. Supreme Court’s decision in *Loper Bright Enterprises v. Raimondo*, which curtailed the long-standing doctrine of judicial deference to federal agency interpretations of ambiguous statutes. Without that deference, courts may be more willing to independently assess whether FDA approval practices comply with statutory requirements.

Additionally, Sipes warns that the program could also expose drug manufacturers to product liability claims. If a patient were harmed by a therapy approved through the expedited review pathway, plaintiffs might argue that the risks were insufficiently evaluated during the abbreviated review process. Successful “failure-to-warn” claims could force manufacturers to revise product labeling or add additional restrictions.